Skip to content

Study · Non-randomized trial · n = 9 · 1993

9 results

Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations.

Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson BA

Arteriosclerosis and thrombosis : a journal of vascular biology1 Feb 1993Cited by 122 (Europe PMC)

PMID8427864 (opens in a new tab)DOI10.1161/01.atv.13.2.296 (opens in a new tab)PepBankPUB-08427864
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, GH increased lipoprotein (a) to about twice pretreatment levels.

    In plain wordsIn adults with pituitary insufficiency, GH increased lipoprotein (a) compared with pretreatment levels.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLipoprotein (a)
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Lipoprotein (a) concentrations increased markedly during treatment and were about twice as high compared with pretreatment levels.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, GH decreased serum cholesterol at 6 weeks, with return to pretreatment levels at 26 weeks.

    In plain wordsIn adults, GH lowered cholesterol at 6 weeks, but levels returned to pretreatment levels at 26 weeks.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedSerum cholesterol
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum cholesterol and low density lipoprotein cholesterol concentrations were decreased after 6 weeks of treatment, but levels had returned to pretreatment levels after 26 weeks.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, GH decreased LDL cholesterol at 6 weeks, with return to pretreatment levels at 26 weeks.

    In plain wordsIn adults, GH lowered LDL cholesterol at 6 weeks, but levels returned to pretreatment levels at 26 weeks.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedLDL cholesterol
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum cholesterol and low density lipoprotein cholesterol concentrations were decreased after 6 weeks of treatment, but levels had returned to pretreatment levels after 26 weeks.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, GH increased HDL cholesterol above pretreatment levels after 26 weeks.

    In plain wordsIn adults with pituitary insufficiency, GH increased HDL cholesterol compared with pretreatment levels.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHDL cholesterol
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    High density lipoprotein cholesterol concentrations increased during treatment and were significantly higher than pretreatment levels after 26 weeks of treatment.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, serum triglycerides did not change significantly during GH treatment.

    In plain wordsIn adults with pituitary insufficiency, triglycerides did not change significantly during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeSerum triglycerides
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum triglyceride concentrations did not change significantly, but in two patients with marked hypertriglyceridemia, growth hormone treatment resulted in a marked decrease.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, apolipoprotein A-I did not change significantly during GH treatment.

    In plain wordsIn adults with pituitary insufficiency, apolipoprotein A-I did not change significantly during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeApolipoprotein A-I
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum concentrations of apolipoproteins A-I, B, and E did not change significantly
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, apolipoprotein B did not change significantly during GH treatment.

    In plain wordsIn adults with pituitary insufficiency, apolipoprotein B did not change significantly during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeApolipoprotein B
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum concentrations of apolipoproteins A-I, B, and E did not change significantly
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In adults with pituitary insufficiency, apolipoprotein E did not change significantly during GH treatment.

    In plain wordsIn adults with pituitary insufficiency, apolipoprotein E did not change significantly during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeApolipoprotein E
    Study

    n = 9

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum concentrations of apolipoproteins A-I, B, and E did not change significantly
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.
  9. 09HumanNon-randomized trialEfficacy outcome

    In two patients with marked hypertriglyceridemia, GH markedly decreased triglycerides.

    In plain wordsIn two patients with high triglycerides, GH markedly lowered triglycerides.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTriglycerides in marked hypertriglyceridemia
    Study

    n = 2

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.25-0.5 units/kg per week · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum triglyceride concentrations did not change significantly, but in two patients with marked hypertriglyceridemia, growth hormone treatment resulted in a marked decrease.
    2 context sentences
    Summary · context
    Nine patients, one women and eight men (age range, 34-58 years), who had been treated for pituitary tumors were studied.
    Summary · context
    The study had a double-blind, placebo-controlled, crossover design for active treatment with recombinant human growth hormone (0.25-0.5 units/kg per week s.c. given each evening) for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.